Transient Ischemic Attack

Clinical Trial Finder

Many patients who experience transient ischemic attacks (TIAs) are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Not yet recruiting - verified April 2014

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Discharge Educational Strategies for Reduction of Vascular Events

Conditions:   Intracerebral Infarcts;   Ischemic Stroke;   Hemorrhagic Strokes;   TIA's
Intervention:   Behavioral: DESERVE education
Sponsors:   New York University School of Medicine;   Columbia University;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2014

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified April 2014

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)

Conditions:   Carotid Stenosis;   Atherosclerosis;   Stroke;   Transient-ischaemic Attack;   TIA;   Amaurosis Fugax
Interventions:   Drug: Revacept;   Drug: Placebo
Sponsor:   AdvanceCor GmbH
Recruiting - verified April 2014

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified April 2014

Cardiovascular and Torsades de Pointes Monitoring for Pazopanib

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: Pazopanib;   Drug: Other anti-VEGFs
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2014

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy

Conditions:   Carotid Artery Disease;   Stroke;   Amaurosis Fugax;   Transient Ischemic Attack (TIA)
Intervention:   Device: RX Acculink Carotid Stent System (RX Acculink)
Sponsor:   Abbott Vascular
Active, not recruiting - verified April 2014

Carotid Plaque Imaging in Acute Stroke

Conditions:   Stroke;   Ischemic Attack, Transient
Intervention:  
Sponsors:   Ludwig-Maximilians - University of Munich;   Technische Universität München
Recruiting - verified April 2014

Management Practices and the Risk of Infection Following Cardiac Surgery

Conditions:   Cardiac Surgery;   Infection, Postoperative Wound;   Postoperative Wound Infection;   Infections, Nosocomial;   Management Practices
Intervention:  
Sponsors:   Mount Sinai School of Medicine;   National Heart, Lung, and Blood Institute (NHLBI);   Canadian Institutes of Health Research (CIHR);   National Institute of Neurological Disorders and Stroke (NINDS)
Completed - verified April 2014

Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)

Conditions:   Arterial Thromboembolic Events;   Atrial Fibrillation
Interventions:   Drug: Placebo;   Drug: Dalteparin
Sponsors:   Duke University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2014

Get CardioSmart

You're Invited